Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd

References

• SEER: Surveillance, epidemiology, and end results program; cancer stat facts: myeloma. [cited 2019 Sep 17]. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html
   Google Scholar
• Howell D, Smith A, Appleton S, et al. Multiple myeloma: routes to diagnosis, clinical characteristics and survival – findings from a UK population-based study. Br J Haematol. 2017;177:67–71.
   PubMed Web of Science ®Google Scholar
• Pozzi S, Marcheselli L, Bari A, et al. Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. Br J Haematol. 2013;163:40–46.
   PubMed Web of Science ®Google Scholar
• Rondeau V, Cornet E, Moreau P, et al. Prediction of patients with multiple myeloma eligible for second- or third-line treatment in France. Ann Hematol. 2016;95:1307–1313.
   PubMed Web of Science ®Google Scholar
• Al-Hamadani M, Hashmi SK, Go RS. Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents. Am J Hematol. 2014;89:825–830.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–1128.
   PubMed Web of Science ®Google Scholar
• Durie B, Hoering A, Abidi M, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017a;389:519–527.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Xie P, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014;123(10):1461–1469.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulus MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–152.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621–1634.
   PubMed Web of Science ®Google Scholar
• Chari A, Romanus D, Palumbo A, et al. Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):8–17.e16.
   PubMed Web of Science ®Google Scholar
• Richardson PG, San Miguel JF, Moreau P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018 Nov 9;8(11):109.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068–2074.
   PubMed Web of Science ®Google Scholar
• Cook G, Jackson GH, Morgan GJ, et al. The outcome of high-dose chemotherapy and auto-SCT in patients with multiple myeloma: a UK/Ireland and European benchmarking comparative analysis. Bone Marrow Transpl. 2011;46:1210–1218.
   PubMed Web of Science ®Google Scholar
• Chan EHL, De-Silva D, Lin AHF, et al. Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centres. Br J Haematol. 2019;186(1):162–165.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Larocca A, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol. 2014;32(7):634–640.
   PubMed Web of Science ®Google Scholar
• Van Beurden-Tan CHY, Blommestein HM, Zweegman S, et al. The relationship of response on time to next treatment based on evidence from two RCTs in newly diagnosed stem cell transplantation ineligible multiple myeloma patients. Blood. 2016;128(22):2141.
   Web of Science ®Google Scholar
• Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity derived from ICD-9-CCM administrative data. Med Care. 2002 Aug;40(8):675–685.
   PubMed Web of Science ®Google Scholar
• Nash Smyth E, Conti I, Wooldridge JE, et al. Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma. J Med Econ. 2016;19(5):477–486.
   PubMed Web of Science ®Google Scholar
• NCCN.org [Internet]. National comprehensive cancer network clinical practice guidelines in oncology (NCCN Guidelines®) for Multiple Myeloma V.1.2020. [cited 2019 Sept 18]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf.
   Google Scholar
• Rajkumar SV, Harousseau JL, Durie B, et al. International myeloma workshop consensus panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International myeloma workshop consensus panel 1. Blood. 2011;117(18):4691–4695.
   PubMed Web of Science ®Google Scholar
• Usmani S, Ahmadi T, Ng Y, et al. Analysis of real-world data on overall survival in MM patients with ≥3 prior lines of therapy including a PI and an IMID, or double refractory to a PI and an IMID. Oncologist. 2016;21:1–7.
   PubMed Web of Science ®Google Scholar
• Danhof S, Schreder M, Rasche L, et al. Efficacy and safety of pre-approval carfilzomib-based therapy of multiple myeloma in daily practice - experience from a German academic center. Clin Lymphoma Myeloma Leuk. 2015;15(3):e284.
   Google Scholar
• Durie B, Cook G, Goldschmidt H, et al. The use of carfilzomib and bortezomib in routine clinical practice: results from preamble, an ongoing, observational cohort study in multiple myeloma. Haematologica. 2017b;102(s2):520. Abstract E1269.
   Google Scholar
• Cerchione C, Ferrara K, Peluso I, et al. Carfilzomib-lenalidomide-dexamethasone in the management of relapsed and refractory multiple myeloma: a real-life experience. Haematologica. 2017;102(S2):804.
   Google Scholar
• Hobbs M, Paludo J, Fonder A, et al. Efficacy of carfilzomib (K), pomalidomide (P), and dexamethasone (d) in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM) in a real world setting. Blood. 2016;128:3337.
   Web of Science ®Google Scholar
• Romanus D, Raju A, Yong C, et al. Association between treatment regimen type in second-line therapy (2LT) and duration of therapy (DOT) & time to next treatment (TTNT) in a United States (US) relapsed/refractory multiple myeloma (RRMM) Cohort. Clin Lymphoma Myeloma Leuk. 2017;17(1 supplement):e81–e82.
   Google Scholar
• Hajek R, Terpos E, Lee HC, et al. Lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma (MM) patients (Pts) - effectiveness in routine clinical practice is similar to the efficacy in the phase 3 TOURMALINE-MM1 trial: a pooled analysis from the Insight MM observational study and the czech registry of monoclonal gammopathies (RMG). Blood. 2018;132(Suppl 1):1971.
   Google Scholar
• Minarik J, Krhovska P, Jelinek T, et al. Treatment of relapsed and refractory multiple myeloma with fully oral triplet IRD (ixazomib, lenalidomide and dexamethasone) is safe and with significant therapeutic outcomes. Blood. 2018;132(Suppl 1):1959.
   Google Scholar
• Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018 Jan 18;131(3):301–310.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Mateos MV, Zweegman S, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98:980–987.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Richardson PG, Dimopoulos MA, et al. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol. 2015;90(4):314–319.
   PubMed Web of Science ®Google Scholar
• Hari P, Romanus D, Palumbo A, et al. Prolonged duration of therapy is associated with improved survival in patients treated for relapsed/refractory multiple myeloma in routine clinical care in the United States. Clin Lymphoma Myeloma Leuk. 2018;18:152–160.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Accordino MK, Shen S, et al. Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. Cancer. 2020:1–9. doi: 10.1002/cncr.32690
   PubMed Web of Science ®Google Scholar
• Heslinga M, Nielen MMJ, Smulders Y, et al. Amplified prevalence and incidence of cardiovascular disease in patients with inflammatory arthritis and coexistent autoimmune disorders. Rheumatology. 2020:1–7. pii: kez650. doi: 10.1093/rheumatology/kez650.
   Google Scholar
• Rifkin RM, Abonour R, Terebelo H, et al. Connect MM Registry: the importance of establishing baseline disease characteristics. Clin Lymphoma Myeloma Leuk. 2015;15(6):368–376.
   PubMed Web of Science ®Google Scholar